2003
DOI: 10.1007/s00424-003-1163-3
|View full text |Cite
|
Sign up to set email alerts
|

Ser 16 -, but not Thr 17 -phosphorylation of phospholamban influences frequency-dependent force generation in human myocardium

Abstract: Beta-adrenoceptor/cAMP-dependent Ser16-phosphorylation as well as Ca(2+)-dependent Thr17-phosphorylation of phospholamban (PLB) influences SERCA 2a activity and thus myocardial contractility. To determine the cross-signaling between Ca2+ and cAMP pathways, the phosphorylation of Ser16-PLB and Thr17-PLB was studied at increasing stimulation frequencies as well as in the presence of beta-adrenergic stimulation in isolated ventricular trabeculae from failing (dilative cardiomyopathy, DCM, heart transplants, n=9) … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
15
0

Year Published

2004
2004
2018
2018

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 31 publications
(15 citation statements)
references
References 36 publications
(42 reference statements)
0
15
0
Order By: Relevance
“…However, in the MOD phenotype, expression of NCX‐1 was increased and phosphorylation of phospholamban at S16 was decreased relative to sham and the other phenotypes (Figure 6A). While LVEF was preserved in the MOD phenotype, increases in NCX‐1 and decreased phospholamban phosphorylation are characteristic of humans with and experimental models of overt systolic HF 25, 26, 27, 28, 29…”
Section: Resultsmentioning
confidence: 99%
“…However, in the MOD phenotype, expression of NCX‐1 was increased and phosphorylation of phospholamban at S16 was decreased relative to sham and the other phenotypes (Figure 6A). While LVEF was preserved in the MOD phenotype, increases in NCX‐1 and decreased phospholamban phosphorylation are characteristic of humans with and experimental models of overt systolic HF 25, 26, 27, 28, 29…”
Section: Resultsmentioning
confidence: 99%
“…Limited data exist on the regulation of SERCA2a from human sources, and all data are from explanted hearts at terminal end‐stage HF, that is, a substantially different cohort than the current patients. Notwithstanding this, controversies exist regarding regulation of SERCA2a proteins, where several reports show no change of SERCA2a protein in HF,14, 15, 16, 17, 18, 19, 20 and others show reduced protein levels of SERCA2a 21, 22, 23. Despite the controversies on the extent of SERCA2a protein regulation in human HF, a clinical trial with the aim of increasing the SERCA2a protein levels in patients with HF was designed using recombinant adeno‐associated virus Serotype 1/SERCA2a;24 the initial data from the clinical Phase 1 trial reported promising results,25 but the continued Phase 2b trial failed to improve the clinical course of patients with HF and reduced EF 26.…”
Section: Discussionmentioning
confidence: 99%
“…Phosphorylation of both the protein kinase A (PKA) site Ser‐16 and the CaMKII site Thr‐17 relieves the PLB inhibition of SERCA2 and thus increases its capacity to remove cytosolic Ca 2+ . Although reduced PLB phosphorylation is regarded as an important mechanism of lower SERCA2a activity in HF, conflicting results exist from both animal models and the limited work done in human HF; human data from explanted dilated cardiomyopathy hearts with terminal HF found both Ser‐16 and Thr‐17 phosphorylations of PLB to be reduced,15, 16 but a later report found only Ser‐16, but not Thr‐17, phosphorylation to be reduced 17…”
Section: Discussionmentioning
confidence: 99%
“…Second, it is unknown whether EPAC-regulated Ca 2+ homeostasis is important for cardiac function and arrhythmogenesis under physiological conditions. Third, it remains unknown whether EPAC regulates PLN phosphorylation on serine-16 in addition to threonine-17, which is known to be a major regulator of Ca 2+ cycling in the heart and closely associated not only with an increase in cardiac function (16,17,56,57), but also with arrhythmia and cardiomyopathy after chronic catecholamine infusion, aortic banding, or ischemia (18,20,21). We thus generated Epac1 KO and Epac2 KO in addition to silencing EPAC1 with siRNA and selectively inhibiting PKA with Ad-PKI-GFP in cardiac myocytes.…”
Section: Discussionmentioning
confidence: 99%